SRR665298
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.427
- KRAS_SIGNALING_DN+0.391
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.301
- BILE_ACID_METABOLISM+0.191
- ANGIOGENESIS+0.186
- APICAL_SURFACE+0.180
- COAGULATION+0.163
- ALLOGRAFT_REJECTION+0.160
- SPERMATOGENESIS+0.152
- ESTROGEN_RESPONSE_EARLY+0.144
Top 10 suppressed
- MYC_TARGETS_V1-0.530
- CHOLESTEROL_HOMEOSTASIS-0.465
- UNFOLDED_PROTEIN_RESPONSE-0.457
- E2F_TARGETS-0.455
- G2M_CHECKPOINT-0.442
- DNA_REPAIR-0.439
- MYC_TARGETS_V2-0.432
- MTORC1_SIGNALING-0.416
- PROTEIN_SECRETION-0.329
- UV_RESPONSE_UP-0.301
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR614155 | GTEX | — | 0.925 |
| 2 | SRR614479 | GTEX | — | 0.921 |
| 3 | SRR612731 | GTEX | — | 0.914 |
| 4 | SRR1330675 | GTEX | — | 0.909 |
| 5 | SRR598276 | GTEX | — | 0.905 |
| 6 | SRR614814 | GTEX | — | 0.904 |
| 7 | SRR1375635 | GTEX | — | 0.900 |
| 8 | SRR1329761 | GTEX | — | 0.900 |
| 9 | SRR612899 | GTEX | — | 0.898 |
| 10 | SRR1434138 | GTEX | — | 0.897 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.427 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.391 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.301 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.191 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.186 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| COAGULATION | 0.163 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.160 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.152 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.144 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.140 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.139 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.125 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.110 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.086 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.079 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.027 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.013 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.007 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.001 | Inavolisib | — uncovered |